London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.

London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.

Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics.

Psyomics has launched beseen for neurodiversity, a new digital tool that supports NHS services struggling to meet the demand of neurodevelopmental referrals and backlogs.

Unique, easy-to-use lightweight incubator enables care anywhere and everywhere while avoiding separation of mother and baby

Potential for novel incubator to address key aspects of preterm neonatal care and reduce dependence on NICU

Axol Bioscience, which has facilities in Cambridge and Edinburgh, has raised $2.8 million (£2.1m) funding to accelerate product development, scale up cell manufacturing and progress US expansion plans.

Oxford Space Systems and Surrey Satellite Technology Ltd (SSTL) have announced the successful launch of CarbSAR IOD, SSTL’s latest Synthetic Aperture Radar (SAR) technology demonstration satellite incorporating Oxford Space Systems’ innovative Wrapped Rib Antenna. The spacecraft was launched aboard a Falcon 9 rocket operated by SpaceX from Vandenberg Space Force Base, California.

Nova Pangaea Technologies, the sustainable aviation fuel specialist backed by International Airlines Group, has appointed veteran cleantech leader Stewart Stewart as CEO.

The National Cyber Resilience Centre Group (NCRCG) has welcomed CyberSmart as a National Ambassador to support UK SMEs and MSPs in strengthening cyber-resilience.

Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, marking a significant step forward for the Oxford-based AI drug discovery company.

Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Rebecca Simmons as Chief Operating Officer.

Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Dr Steven Bishop as Chief Medical Officer (CMO). Previously Chief Data Officer, Steven’s new role reflects changes in company structure, in response to continued growth and commercial success.